182 related articles for article (PubMed ID: 15930983)
1. The pathophysiologic rationale for biological therapies in inflammatory bowel disease.
Gordon JN; Di Sabatino A; Macdonald TT
Curr Opin Gastroenterol; 2005 Jul; 21(4):431-7. PubMed ID: 15930983
[TBL] [Abstract][Full Text] [Related]
2. New mediators of immunity and inflammation in inflammatory bowel disease.
Monteleone G; Fina D; Caruso R; Pallone F
Curr Opin Gastroenterol; 2006 Jul; 22(4):361-4. PubMed ID: 16760750
[TBL] [Abstract][Full Text] [Related]
3. Immune mechanisms in chronic inflammatory bowel disease.
Braegger CP; MacDonald TT
Ann Allergy; 1994 Feb; 72(2):135-41. PubMed ID: 8109803
[TBL] [Abstract][Full Text] [Related]
4. Immune dysfunction in inflammatory bowel disease.
Neuman MG
Transl Res; 2007 Apr; 149(4):173-86. PubMed ID: 17383591
[TBL] [Abstract][Full Text] [Related]
5. Homeostatic (IL-7) and effector (IL-17) cytokines as distinct but complementary target for an optimal therapeutic strategy in inflammatory bowel disease.
Kanai T; Nemoto Y; Kamada N; Totsuka T; Hisamatsu T; Watanabe M; Hibi T
Curr Opin Gastroenterol; 2009 Jul; 25(4):306-13. PubMed ID: 19448533
[TBL] [Abstract][Full Text] [Related]
6. Review article: the aetiopathogenesis of inflammatory bowel disease--immunology and repair mechanisms.
Dignass AU; Baumgart DC; Sturm A
Aliment Pharmacol Ther; 2004 Oct; 20 Suppl 4():9-17. PubMed ID: 15352888
[TBL] [Abstract][Full Text] [Related]
7. Excess IL-12 but not IL-23 accompanies the inflammatory bowel disease associated with common variable immunodeficiency.
Mannon PJ; Fuss IJ; Dill S; Friend J; Groden C; Hornung R; Yang Z; Yi C; Quezado M; Brown M; Strober W
Gastroenterology; 2006 Sep; 131(3):748-56. PubMed ID: 16952544
[TBL] [Abstract][Full Text] [Related]
8. Immunological disorders in inflammatory bowel disease and immunotherapeutic implications.
Amati L; Caradonna L; Jirillo E; Caccavo D
Ital J Gastroenterol Hepatol; 1999 May; 31(4):313-25. PubMed ID: 10425578
[TBL] [Abstract][Full Text] [Related]
9. Signaling for inflammation and repair in inflammatory bowel disease.
Neuman MG
Rom J Gastroenterol; 2004 Dec; 13(4):309-16. PubMed ID: 15624029
[TBL] [Abstract][Full Text] [Related]
10. After interleukin-12p40, are interleukin-23 and interleukin-17 the next therapeutic targets for inflammatory bowel disease?
Zhang Z; Hinrichs DJ; Lu H; Chen H; Zhong W; Kolls JK
Int Immunopharmacol; 2007 Apr; 7(4):409-16. PubMed ID: 17321463
[TBL] [Abstract][Full Text] [Related]
11. Mucosal T cells as a target for treatment of IBD.
Watanabe M; Yamazaki M; Kanai T
J Gastroenterol; 2003 Mar; 38 Suppl 15():48-50. PubMed ID: 12698871
[TBL] [Abstract][Full Text] [Related]
12. Immunotherapy of inflammatory bowel diseases: current concepts and future perspectives.
Neurath MF
Arch Immunol Ther Exp (Warsz); 2000; 48(2):81-4. PubMed ID: 10807047
[TBL] [Abstract][Full Text] [Related]
13. Evolving knowledge and therapy of inflammatory bowel disease.
Korzenik JR; Podolsky DK
Nat Rev Drug Discov; 2006 Mar; 5(3):197-209. PubMed ID: 16518373
[TBL] [Abstract][Full Text] [Related]
14. Genetic and spontaneous models of inflammatory bowel disease in rodents: evidence for abnormalities in mucosal immune regulation.
Powrie F; Leach MW
Ther Immunol; 1995 Apr; 2(2):115-23. PubMed ID: 8729882
[TBL] [Abstract][Full Text] [Related]
15. Gene transfer approaches for the treatment of inflammatory bowel disease.
Wirtz S; Neurath MF
Gene Ther; 2003 May; 10(10):854-60. PubMed ID: 12732871
[TBL] [Abstract][Full Text] [Related]
16. Interleukin-25 inhibits interleukin-12 production and Th1 cell-driven inflammation in the gut.
Caruso R; Sarra M; Stolfi C; Rizzo A; Fina D; Fantini MC; Pallone F; MacDonald TT; Monteleone G
Gastroenterology; 2009 Jun; 136(7):2270-9. PubMed ID: 19505427
[TBL] [Abstract][Full Text] [Related]
17. The role of the novel Th17 cytokine IL-26 in intestinal inflammation.
Dambacher J; Beigel F; Zitzmann K; De Toni EN; Göke B; Diepolder HM; Auernhammer CJ; Brand S
Gut; 2009 Sep; 58(9):1207-17. PubMed ID: 18483078
[TBL] [Abstract][Full Text] [Related]
18. Physiological basis for novel drug therapies used to treat the inflammatory bowel diseases. I. Immunology and therapeutic potential of antiadhesion molecule therapy in inflammatory bowel disease.
Van Assche G; Rutgeerts P
Am J Physiol Gastrointest Liver Physiol; 2005 Feb; 288(2):G169-74. PubMed ID: 15647604
[TBL] [Abstract][Full Text] [Related]
19. Biologic therapy for inflammatory bowel disease.
Ardizzone S; Bianchi Porro G
Drugs; 2005; 65(16):2253-86. PubMed ID: 16266194
[TBL] [Abstract][Full Text] [Related]
20. Beyond tumor necrosis factor: next-generation biologic therapy for inflammatory bowel disease.
Podolsky DK
Dig Dis; 2009; 27(3):366-9. PubMed ID: 19786766
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
